(Q38101993)

28 August 2017

Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis (English)

1 reference

28 August 2017

Andre Scheen

1

1 reference

PubMed ID

23621381

28 August 2017

language of work or name

English

0 references

publication date

27 April 2013

1 reference

Expert Opinion on Drug Safety

28 August 2017

1 reference

28 August 2017

12

1 reference

28 August 2017

4

1 reference

28 August 2017

545-557

1 reference

Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus

28 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.793671

A review of gliptins in 2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.793671

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.793671

DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.793671

Cardiovascular effects of gliptins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.793671

Pharmacokinetics of dipeptidylpeptidase-4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.793671

Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.793671

Sitagliptin: a review of its use in the management of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.793671

Vildagliptin: a review of its use in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.793671

Saxagliptin: a review of its use as combination therapy in the management of type 2 diabetes mellitus in the EU.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.793671

Alogliptin: a review of its use in the management of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.793671

Linagliptin: in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.793671

Safety of dipeptidyl peptidase 4 inhibitors for treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.793671

Tolerability of dipeptidyl peptidase-4 inhibitors: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.793671

Glucagon-like peptide-1 therapy and the exocrine pancreas: innocent bystander or friendly fire?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.793671

Association of pancreatitis with glucagon-like peptide-1 agonist use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.793671

A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.793671

The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.793671

Dipeptidylpeptidase-4 (DPP-4) inhibitors are favourable to glucagon-like peptide-1 (GLP-1) receptor agonists: yes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.793671

Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.793671

Mechanisms of action of glucagon-like peptide 1 in the pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.793671

GLP-1-based therapy for diabetes: what you do not know can hurt you.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.793671

Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.793671

Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.793671

Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.793671

Acute pancreatitis in association with type 2 diabetes and antidiabetic drugs: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.793671

Type 2 diabetes mellitus and the risk of acute pancreatitis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.793671

Mechanisms of parenchymal injury and signaling pathways in ectatic ducts of chronic pancreatitis: implications for pancreatic carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.793671

GLP-1-based therapies and the exocrine pancreas: more light, or just more heat?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.793671

Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.793671

The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.793671

Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.793671

Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.793671

Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.793671

Studies in rodents with the dipeptidyl peptidase-4 inhibitor vildagliptin to evaluate possible drug-induced pancreatic histological changes that are predictive of pancreatitis and cancer development in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.793671

Pancreatitis associated with the use of sitagliptin and orlistat combination: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.793671

Case report of acute necrotizing pancreatitis associated with combination treatment of sitagliptin and exenatide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.793671

A case of severe acute necrotizing pancreatitis after administration of sitagliptin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.793671

Pancreatitis with pancreatic tail swelling associated with incretin-based therapies detected radiologically in two cases of diabetic patients with end-stage renal disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.793671

GLP-1-based therapies: the dilemma of uncertainty.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.793671

Do incretin-based therapies cause acute pancreatitis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.793671

Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.793671

Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.793671

Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.793671

An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.793671

Efficacy and safety of saxagliptin combination therapy in US patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.793671

Saxagliptin and sitagliptin in adult patients with type 2 diabetes: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.793671

Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.793671

Alogliptin benzoate for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.793671

Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.793671

Efficacy of alogliptin in type 2 diabetes treatment: a meta-analysis of randomized double-blind controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.793671

Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.793671

GLP-1 based agents and acute pancreatitis : drug safety falls victim to the three monkey paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.793671

Postmarketing surveillance and adverse drug reactions: current perspectives and future needs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.793671

A cohort study of acute pancreatitis in relation to exenatide use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.793671

Exenatide therapy and the risk of pancreatitis and pancreatic cancer in a privately insured population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.793671

Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.793671

Pancreatitis: a potential complication of liraglutide?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.793671

The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.793671

Benefit-risk assessment of exenatide in the therapy of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.793671

Weighing risks and benefits of liraglutide--the FDA's review of a new antidiabetic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.793671

Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.793671

Baseline characteristic differences between patients prescribed sitagliptin vs. other oral antihyperglycemic agents: analysis of a US electronic medical record database

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.793671

The safety of incretin-based therapies--review of the scientific evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.793671

Incretin-based therapies in the treatment of type 2 diabetes--more than meets the eye?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.793671

Dipeptidyl peptidase-4 (DPP-4) inhibitors are favourable to Glucagon-Like Peptide-1 (GLP-1) agonists: No

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.793671

10.1517/14740338.2013.793671

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference

PubMed ID

23621381